Oncogenic Kras initiates leukemia in hematopoietic stem cells
about
Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks.Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.Induction of histiocytic sarcoma in mouse skeletal muscle.Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemiaGerminal center B-cells resist transformation by Kras independently of tumor suppressor ArfDefining the origins of Ras/p53-mediated squamous cell carcinomaEndogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.KRas(G12D)-evoked leukemogenesis does not require β-catenin.A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells.Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesisIGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.Targeting oncogenic Ras signaling in hematologic malignancies.Functional and molecular characterization of mouse Gata2-independent hematopoietic progenitorsLoss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.Basal stem cells contribute to squamous cell carcinomas in the oral cavity.Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivoNotch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functionsHematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cellsLoss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic TargetingMolecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Differential cell growth/apoptosis behavior of 13-hydroxyoctadecadienoic acid enantiomers in a colorectal cancer cell line.KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis.
P2860
Q28383732-861BE05A-96BA-4235-B7A4-E1DE9CFD1258Q33685977-0A373C7D-4852-412C-9E75-DB20FF267636Q33718376-914C479E-C140-4448-A2EE-C02D5D29A3CAQ33739961-8FE2429B-F8DA-46C3-93BA-35B56A517F56Q33871210-0F8AF7ED-0617-4CC6-B7B8-F94A673A8AC5Q33953631-77E8BD48-37F6-47C6-9E5D-D9FAA8549B6BQ34027499-1A98B8F7-A2AC-45F0-AE8C-E815F5E63E5BQ34099193-F488C82F-40E2-473A-AF17-0806844982F0Q34284326-2651C8D9-16A4-4B89-BFC2-FA3EDFC192D6Q34406138-702DB812-B517-49A2-B90C-00CE91020C19Q34541588-651B6B4D-79C9-4CCD-82E1-158E1BCAD266Q34795181-D096417B-BE28-476B-8D9F-D98F5A6DEA7FQ34937383-2E679D11-C44F-4D4B-9859-4E93F4C18823Q35112241-ECD6ACDE-FD8F-4E89-BA77-FE9BCED47319Q35201278-8485F94C-AF84-48AF-A753-D96609BA2BA4Q35692793-1372FD30-87B8-4678-9FFE-99F728C25C9BQ35748498-E5561D34-4219-4D9A-8ED7-A73DB1A715C2Q35757427-E859B26A-3A36-41C7-A5E1-690EEA95CA45Q36021698-F0434FB9-13B0-4716-8D3C-C0DEF47ED85EQ36105608-FD104C04-C0C0-4149-8E3C-76ABBA37E2B3Q36352506-345B7679-27C4-4CB1-ACF2-B5041EC52A73Q36700477-40BD0582-E3AA-4733-91D8-4457C6523A6CQ36700822-C4545C0E-63ED-4322-9AB5-57ED07A25A35Q36813991-D9BABAA6-9374-4E3A-825D-FE30F85E1239Q36928333-E515D7AD-E3FB-4A54-8390-8D8C83226ABBQ36947793-1E0E75DE-C74E-4CEE-813C-58B9AFCA0A3BQ36957609-4AC76630-8EDE-4FD1-ACBA-28F0FAFD3F11Q36962687-B437B4F2-A7A9-41E1-8A69-3BC8D91CCC9AQ37407268-8B350282-88EA-495F-ACDF-8763CD95ACC1Q37635287-987ABA45-4620-4E87-9EC3-8C0A2C6FFA41Q37640929-653A8F72-373B-49D2-A45D-5AD4EF736740Q37651582-E4F3F92A-55CA-40B6-B767-6116A765BE92Q37822317-FFD88C75-FB8C-4442-8D71-8ACB75771FEFQ38227885-F1D5F8F9-C48A-44FB-9ED9-112F76E09DAFQ38248429-363C8EA7-F7BA-4C5B-9C37-9043F9DACD9EQ38285175-D0C6F2F4-91B0-48BC-9843-C1F6537B2FE6Q38974480-E81AB12D-F974-41A0-B55C-F66D6B4AFBCBQ39618355-F97B3858-20B4-404F-925F-7A6F6685AB4FQ40094852-4ACA2753-6B4F-481A-8B67-D9D2B30165CEQ41866413-94D936EB-D77A-4476-8609-F80B48C9BC28
P2860
Oncogenic Kras initiates leukemia in hematopoietic stem cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@ast
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@en
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@nl
type
label
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@ast
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@en
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@nl
prefLabel
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@ast
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@en
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@nl
P2093
P2860
P3181
P1433
P1476
Oncogenic Kras initiates leukemia in hematopoietic stem cells
@en
P2093
Benjamin S Braun
Emmanuelle Passegué
Hio Chung Kang
Kevin Shannon
Laurene S Cheung
Marianne Santaguida
Michelle L Hermiston
Monique Dail
P2860
P3181
P356
10.1371/JOURNAL.PBIO.1000059
P407
P577
2009-03-17T00:00:00Z